<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3993994/" ref="ordinalpos=2619&amp;ncbi_uid=6041732&amp;link_uid=PMC3993994" image-link="/pmc/articles/PMC3993994/figure/F1/" class="imagepopup">Figure 1.  From: LIPID A-MEDIATED TOLERANCE AND CANCER THERAPY. </a></div><br /><div class="p4l_captionBody">Schematic diagram of hypothetical mechanisms of tolerance within the TLR4 pathway. While ST2, IRAK-M, and the splice variant of MyD88 (MyD88s) are thought to suppress association of IRAK-1 with MyD88 through competitive inhibition. TOLLIP has been shown to bind to IRAK-1 and inhibits its activity. SOCS-1 and SOCS-3 are inhibitors of the JAK/STAT pathway. While the mechanism by which SHIP induces tolerance is unknown, it is believed to inhibit the NFÎºB signaling pathway.</div></div>